



C2C BUSINESS STRATEGIES LLC

Financial Research & Publications Group

Specializing in Comprehensive Financial Reports for Public and Private
Lower Middle Market Companies

Strategic Risk & Opportunity Assessment Report



epiMedTech Global

Prepared by:
C2C Business Strategies LLC
Date: July 2025

Safe Harbor Statement

The business reviews presented by C2C Business Strategies, LLC may contain forward-looking statements made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such statements.

Disclaimer

This business review is **NOT** a solicitation to buy or sell any security. It is provided solely for informational purposes. The content reflects facts, views, opinions, and recommendations from individuals and organizations both related and unrelated to C2C Business Strategies, LLC. C2C Business Strategies LLC does not guarantee the accuracy, completeness, or timeliness of any information presented, nor does it endorse any views, opinions, or recommendations contained herein, or provide investment advice.

C2C Business Strategies, LLC's mission is to provide and disseminate useful information on small public & private companies through business reviews and summaries. This information is intended for educational and informational purposes only and should not be construed as investment advice or an endorsement of any company discussed.

C2C Business Strategies LLC has not received compensation for this business review and does not anticipate any such compensation from the subject company or its affiliates. The business review is made available to the public via C2C Business Strategies, LLC's electronic distribution.

Investment Risk Notice:

Investments in small-cap companies involve a high degree of risk, which can vary significantly

1370 NC 24-87 STE 153 - CAMERON, NC 28326

919.694.7028 - INFO@C2CPIC.COM - C2CBUSINESS.COM

Executive Summary

epiMedTech Global is a rapidly growing medical technology company focused on developing and commercializing advanced diagnostic and therapeutic solutions for neurological disorders and minimally invasive procedures. Headquartered in Boston, Massachusetts, the company reported approximately \$22 million in revenue in 2023, reflecting strong adoption of its neuromodulation devices and surgical guidance systems. epiMedTech continues to innovate and expand its portfolio while exploring international growth opportunities and strategic partnerships.

1. Company Overview

- Legal Name: epiMedTech Global, Inc.
- Headquarters: Boston, Massachusetts, USA.
- Founded: 2015.
- Industry: Medical Technology & Devices.
- Business Model: Development and commercialization of neurology-focused medical devices and surgical systems.
- Key Markets: North America, Europe, Asia-Pacific.
- Employees: ~250.
- Market Position: Emerging leader in advanced neuro and minimally invasive surgical technologies.

2. Leadership and Founding Team

- Dr. Emily Carter: CEO & Co-founder; recognized expert in neuroengineering and medical device innovation.
- Board & Executive Team: Broad expertise in neuroscience, clinical research, and global medical device commercialization.

3. Product/Service Portfolio, Market Position & Peer Analysis

- Core Products: Neuromodulation devices for epilepsy and chronic pain; advanced intraoperative monitoring and navigation systems.
- Market Position: Positioned as an innovator in precise neurological intervention solutions.
- Peers: Medtronic, Boston Scientific (neuromodulation); Stryker (surgical guidance systems).
- Differentiators: Proprietary real-time neural mapping technology and miniaturized device design.

4. Financial Performance, Valuation & Benchmarking

- 2023 Revenue: ~\$22M (+29% YoY).
- 5-Year Revenue Trend: Growth from ~\$5M in 2018 to ~\$22M in 2023 (CAGR ~32%).
- Gross Margin: ~68%, reflecting premium pricing and advanced IP.

- Operating Income: Positive trajectory; reinvestment into R&D limits short-term profits.
- Market Cap: ~\$180M (2024, estimated private valuation).
- Key Considerations: High R&D spending continues to drive technological leadership but requires careful cash flow management.

5. M&A and Transactional Activity

- 2021: Acquired NeuroNav Systems to expand surgical navigation capabilities.
- 2022: Strategic partnership with European distributor to accelerate EU market entry.
- Future Strategy: Evaluate acquisition targets in neuroimaging and robotics for portfolio synergies.

6. SWOT Analysis

- Strengths: Proprietary technology; high gross margins; strong clinical validation.
- Weaknesses: Heavy reliance on continued R&D investment; relatively small scale.
- Opportunities: International expansion; new indications (e.g., stroke, movement disorders).
- Threats: Large incumbent competitors; regulatory hurdles; reimbursement landscape shifts.

7. Strategic Recommendations

- Expand European and Asia-Pacific presence through strategic partnerships and local certifications.
- Accelerate pipeline development for new neurological indications to diversify revenue streams.
- Strengthen manufacturing scalability to support future global growth.
- Enhance payer engagement to secure favorable reimbursement outcomes.

8. Customer Segmentation & Deep Dive

- Neurosurgeons & Interventional Neurologists: Core end-users focused on surgical precision and improved outcomes.
- Hospitals & Specialty Clinics: Institutions seeking state-of-the-art neuro and minimally invasive capabilities.
- Global Distributors: Key partners for expanding outside North America.
- Investors: Medtech-focused institutional and strategic healthcare investors.

9. Sales & Distribution Strategy Analysis

- Direct Sales: Core U.S. hospital systems and leading academic medical centers.
- Distributors: Strong partnerships in Europe and early-stage APAC efforts.
- Service & Training: Comprehensive in-hospital training programs as differentiation strategy.
- Future: Expand hybrid sales model combining direct and third-party distribution.

10. Operational Efficiency Metrics

- Revenue per Employee: ~\$88K.
- Gross Margin: ~68%, supporting continued R&D reinvestment.
- Manufacturing: Lean, vertically integrated processes with strategic outsourcing.

11. Technology & IP Strategy

- Core Strength: Proprietary neural mapping and device miniaturization platforms.
- IP Portfolio: Patents covering device designs, software algorithms, and surgical workflows.
- Future Plans: Expand IP to cover new neurological indications and combination device-drug therapies.

12. Risk Heatmap

- Regulatory Approval Risk – High.
- Market Competition – Medium.
- Technology Adoption Risk – Medium.
- Reimbursement & Pricing Risk – Medium.
- Supply Chain Risk – Medium.

13. Talent & Culture Review

- Culture: Innovation-driven, cross-disciplinary collaboration, patient outcome focused.
- Leadership: Strong clinical and engineering leadership fostering agile decision-making.
- Retention: High employee engagement tied to mission-critical innovation.

14. Future Capital Strategy & Use of Proceeds

- Fund international market expansion efforts and certifications.
- Support new clinical trials for pipeline programs.
- Enhance manufacturing capacity and operational infrastructure.
- Maintain IP development and strategic partnership initiatives.

15. CEO Strategic Supplement

- Executive Focus: Accelerate global expansion and diversify indication coverage.
- 12–24 Month Targets: Enter two new international markets; complete pivotal trial for stroke application; grow revenue by 35%.
- Immediate Actions: Finalize regulatory submissions; expand distributor partnerships; strengthen talent acquisition.
- Three-Year Vision: Establish epiMedTech Global as a top-tier leader in neurology and precision minimally invasive solutions with robust global presence.

Introduction to the Publisher

C2C Business Strategies Financial Publishing & Research Group:

C2C Business Strategies actively monitors hundreds of lower middle market companies. This includes privately held companies and publicly traded companies across NYSE, NASDAQ, and OTC Markets. Through periodic Strategic Financial & Operational Analysis Reports, we highlight emerging opportunities—while also identifying material risks that could impact performance, valuation, or investor confidence. These insights help stakeholders better understand both the upside potential and the structural vulnerabilities of public micro- and small-cap enterprises.

We specialize in comprehensive financial reports for public and private lower middle market companies, providing detailed, customized financial analysis and reporting for businesses typically generating between \$5 million and \$50 million in annual revenue. These companies occupy a unique space: larger than small businesses, yet not quite large corporations. They often face distinct financial challenges and opportunities. For public companies in this segment, financial reporting must meet strict regulatory standards, ensuring transparency and accuracy for stakeholders and regulators. Private companies, while not subject to the same public scrutiny, still require robust financial reports to inform management decisions, attract investors, and support growth strategies. By focusing on the lower middle market, our expertise ensures that both public and private companies receive the high-quality, actionable financial insights needed to drive performance, maintain compliance, and achieve their strategic goals.

Safe Harbor Statement

The business reviews presented by C2C Business Strategies, LLC may contain forward-looking statements made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such statements.

Disclaimer

This business review is **NOT** a solicitation to buy or sell any security. It is provided solely for informational purposes. The content reflects facts, views, opinions, and recommendations from individuals and organizations both related and unrelated to C2C Business Strategies, LLC. C2C Business Strategies LLC does not guarantee the accuracy, completeness, or timeliness of any information presented, nor does it endorse any views, opinions, or recommendations contained herein, or provide investment advice.

C2C Business Strategies, LLC's mission is to provide and disseminate useful information on small public & private companies through business reviews and summaries. This information is intended for educational and informational purposes only and should not be construed as investment advice or an endorsement of any company discussed.

C2C Business Strategies LLC has not received compensation for this business review and does not anticipate any such compensation from the subject company or its affiliates. The business review is made available to the public via C2C Business Strategies, LLC's electronic distribution.

Investment Risk Notice:

Investments in small-cap companies involve a high degree of risk, which can vary significantly